|
Median age, years (IQR)
|
45 (37–52)
|
4503
|
0
|
|
Female sex, n (%)
|
864 (19)
|
4503
|
0
|
|
Black race, n (%)
|
58 (2)
|
2879
|
1624
|
|
Body mass index, kg/m2 (IQR)
|
22.9 (21.2–24.9)
|
1394
|
3109
|
|
Current smoker, n (%)
|
2110 (51)
|
4154
|
349
|
|
Hypertension, n (%)
|
619 (14)
|
4503
|
0
|
|
Diabetes mellitus, n (%)
|
225 (5)
|
4503
|
0
|
|
Dyslipidemia, n (%)
|
596 (13)
|
4503
|
0
|
|
Cardiovascular disease, n (%)
|
202 (5)
|
4503
|
0
|
|
Hepatitis B coinfection, n (%)
|
149 (3)
|
4485
|
18
|
|
Hepatitis C coinfection, n (%)
|
1006 (22)
|
4495
|
8
|
|
Mode of HIV acquisition, n (%)a
| |
4503
|
0
|
|
Homo/bisexual
|
2650 (62)
| | |
|
Heterosexual
|
1176 (28)
| | |
|
Injection drug use
|
641 (15)
| | |
|
Other/Unknown route
|
290 (6)
| | |
|
Duration of HIV infection, years (IQR)
|
11.3 (5.1–19)
|
4478
|
25
|
|
Prior AIDS (yes), n (%)
|
900 (20)
|
4503
|
0
|
|
Current ART regimen
| |
4503
|
0
|
|
No treatment
|
138 (3)
| | |
|
NNRTI-based
|
2381 (53)
| | |
|
PI-based
|
144 (3)
| | |
|
Boosted PI-based
|
1315 (29)
| | |
|
Integrase inhibitors-based
|
493 (11)
| | |
|
Others
|
32 (1)
| | |
|
Nadir CD4 cell count (IQR)
|
249 (129–369)
|
4484
|
19
|
|
Current CD4 cell count (IQR)
|
628 (450–830)
|
4501
|
2
|
|
Current HIV infection status
| |
4503
|
0
|
|
Suppression on Treatment
|
4031 (90)
| | |
|
No suppression (viral load > 50 copies)
|
471 (10)
| | |
